Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01814488 | A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia(Gandalf-01) | completed | Phase 2 | 101 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT02845297 | Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients | completed | Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Mar 9, 2023 |
| clinicaltrials |
| NCT02269267 | The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) | completed | Phase 2 | 173 | Medical College of WisconsinOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT01238211 | Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Mar 1, 2023 | clinicaltrials |
| NCT01420926 | Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03303339 | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT01066663 | Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT00796068 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | completed | Phase 2 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 96 | Fate TherapeuticsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02810990 | Bosutinib in Elderly Chronic Myeloid Leukemia(BEST) | completed | Phase 2 | 65 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | completed | Phase 1 / Phase 2 | 18 | Precision BioSciences, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML(SOPRA) | completed | Phase 2 | 317 | Karyopharm Therapeutics IncINDUSTRY | 11 | Jan 26, 2023 | clinicaltrials |
| NCT05048615 | Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML | completed | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02807883 | Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03388749 | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 20 | Moleculin Biotech, Inc.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT02758665 | Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL(CLL2-GiVe) | completed | Phase 2 | 41 | University of UlmOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT00551460 | S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | completed | Phase 2 | 78 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00849147 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | completed | Phase 2 | 55 | Medical College of WisconsinOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT01596257 | Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation | completed | Phase 2 | 116 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02996474 | Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 10 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 28, 2022 | clinicaltrials |
| NCT00423514 | Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease | completed | Phase 1 / Phase 2 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT00559091 | A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia(Borden-001) | completed | Phase 2 | 18 | Jewish General HospitalOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | completed | Phase 2 | 14 | AbbVieINDUSTRY | 9 | Dec 19, 2022 | clinicaltrials |
| NCT00864227 | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | completed | Phase 2 | 54 | Medical College of WisconsinOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT00739141 | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | completed | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT01410344 | Allogeneic Transplant in HIV Patients (BMT CTN 0903) | completed | Phase 2 | 20 | Medical College of WisconsinOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02802943 | iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL | completed | Phase 2 | 56 | University Hospital TuebingenOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT02126553 | Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01850004 | Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response(DASFREE) | completed | Phase 2 | 84 | Bristol-Myers SquibbINDUSTRY | 6 | Nov 3, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT01807611 | Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy | completed | Phase 2 | 82 | St. Jude Children's Research HospitalOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT04424147 | Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML | completed | Phase 2 | 96 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01736683 | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Oct 24, 2022 | clinicaltrials |
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | completed | Phase 1 / Phase 2 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT01700673 | Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | completed | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT00475280 | "Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients(LAL1104) | completed | Phase 2 | 102 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01373515 | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 12 | MendusINDUSTRY | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02686593 | Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML | completed | Phase 2 | 50 | The University of Hong KongOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02065154 | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | completed | Phase 2 | 39 | University of Alabama at BirminghamOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT01700946 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | completed | Phase 2 | 80 | St. Jude Children's Research HospitalOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01319981 | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 120 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Sep 19, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT02287233 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 94 | AbbVieINDUSTRY | 4 | Aug 29, 2022 | clinicaltrials |
| NCT00199108 | Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt | completed | Phase 2 / Phase 3 | 20 | Goethe UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2023source: clinicaltrials